ACCESS Newswire

Smart Eye

Share
Smart Eye completes the acquisition of iMotions

GÖTEBORG, SE / ACCESSWIRE / November 25, 2021 / Smart Eye (STO:SEYE)(OTC PINK:SMTEF)(FRA:SE9)

As announced on 26 October 2021, Smart Eye Aktiebolag (publ) ("Smart Eye") entered into an agreement to acquire iMotions A/S ("iMotions"), a provider of multimodal software for human behavior research. Smart Eye has today completed the acquisition of all shares in iMotions.

The purchase price for all shares amounted to approximately MSEK 403, of which approximately MSEK 201 is paid through 1,019,493 newly issued shares in Smart Eye (the "Consideration Shares") that the Board of Directors resolved to issue today. The remaining part of the purchase price, corresponding to approximately MSEK 202, was paid in cash. The price of the Consideration Shares amounts to SEK 197.3931 per share and has been determined based on the volume-weighted average price of Smart Eye's shares on Nasdaq First North Growth Market from 9 August 2021 up to and including the business day immediately prior to the conclusion of the share purchase agreement.

The issue of the Consideration Shares will increase the share capital with SEK 101,949.30 and correspond to approximately 4.60 percent of the share capital and votes in Smart Eye. After registration of the Consideration Shares with the Swedish Companies Registration Office, the number of shares and votes in the Smart Eye will amount to 22,148,650 and the share capital will amount to SEK 2,214,865.

"In the coming decade, we are going to see an expansion of human behavioral research utilizing multimodal approaches, and the addition of iMotions and its multi-sensor integration software gives us the tools to unlock increased value for Smart Eye's customers, particularly in the automotive industry. The future is multimodal with technological advances likely to make it easier, faster and more cost-effective to understand what's driving human behavior and decision making. With iMotions, we're adding multimodal analysis software to our advanced eye tracking and facial expression analysis platform", said Martin Krantz, CEO and Founder of Smart Eye.

For further information regarding the acquisition and about iMotions, please see the press release published on 26 October 2021.

For more information, please contact:
Martin Krantz, CEO Smart Eye AB
Phone: +46 70-329 26 98
Email: martin.krantz@smarteye.se

Anders Lyrheden, CFO Smart Eye AB
Phone: +46 70-320 96 95
Email: anders.lyrheden@smarteye.se

The information was submitted for publication, through the agency of the contact persons set out above, at 3 p.m. CET on 25 November 2021.

SOURCE: Smart Eye



View source version on accesswire.com:
https://www.accesswire.com/674708/Smart-Eye-completes-the-acquisition-of-iMotions

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release

Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e

Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release

BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut

RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye